TEVA Stock Price – News – Teva Pharmaceutical Industries Ltd, teva pharmaceuticals stock.#Teva #pharmaceuticals #stock


Posted On Aug 27 2018 by

Teva Pharmaceutical Industries Ltd. ADR

Nov 30, 2017 4:02 p.m. ET EST

Loading more news…

There is no more news available.

  • Nov 29, 2017 New Migraine Drugs Show Promise in Race to Sell Next-Generation Treatments The Wall Street Journal
  • Nov 28, 2017 Teva shares surge on corporate shake-up MarketWatch.com
  • Nov 27, 2017 Teva’s New CEO Starts Turnaround Plan at Struggling Drugmaker The Wall Street Journal
  • Nov 27, 2017 Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks WSJ Blogs
  • Nov 10, 2017 Why tax-bill fears may be one big contributing factor in junk bond slump MarketWatch.com
  • Nov 8, 2017 Teva’s stock and bonds walloped after Fitch downgrade to junk MarketWatch.com
  • Nov 7, 2017 Why Mallinckrodt’s Woes Matter to All Drug Makers The Wall Street Journal
  • Nov 7, 2017 Teva’s latest quarter was even worse than already-low expectations MarketWatch.com
  • Nov 6, 2017 A Rare Bright Spot for Mylan The Wall Street Journal
  • Nov 2, 2017 Teva’s Rebuild Is Going Nowhere The Wall Street Journal
  • Nov 2, 2017 Teva Cuts Outlook Again in Perfect Storm of Problems The Wall Street Journal
  • Nov 2, 2017 Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt MarketWatch.com
  • Nov 1, 2017 Another Headache for Teva Shareholders WSJ Blogs
  • Oct 31, 2017 States Expand Price-Fixing Accusations Against Generic Drug Companies The Wall Street Journal
  • Oct 23, 2017 Allergan: That $15 Billion Sure Went Fast The Wall Street Journal
  • Oct 23, 2017 Dividend Fears Take Toll on GE Shares The Wall Street Journal
  • Oct 17, 2017 Impax Laboratories and Amneal Pharmaceuticals Agree to Merge The Wall Street Journal
  • Oct 16, 2017 Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement The Wall Street Journal
  • Oct 16, 2017 Allergan Loses Patent Fight in Federal Court The Wall Street Journal
  • Oct 16, 2017 Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening MarketWatch.com

Loading more news…

There is no more news available.

  • Nov 29, 2017 The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine PR Newswires
  • Nov 27, 2017 Teva Announces New Organization Structure and Leadership Changes PR Newswires
  • Nov 15, 2017 Teva Announces Prescription Copay Savings Program for Generic Gleevec(R) Tablets in the United States PR Newswires
  • Nov 2, 2017 Teva Announces Completion of Plan B One-Step(R) Divestiture to Foundation Consumer Healthcare PR Newswires
  • Nov 2, 2017 Teva Reports Third Quarter 2017 Financial Results PR Newswires
  • Nov 1, 2017 Teva Announces Completion of PARAGARD(R) Divestiture to CooperSurgical PR Newswires
  • Nov 1, 2017 FDA s Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks PR Newswires
  • Oct 31, 2017 Teva Wins Generic Uceris(R) Patent Trial PR Newswires
  • Oct 30, 2017 Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017 PR Newswires
  • Oct 26, 2017 Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting PR Newswires
  • Oct 23, 2017 Glancy Prongay Murray Reminds Investors of the October 23rd Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. (TEVA) PR Newswires
  • Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS — ACTRIMS Congress in Paris PR Newswires
  • Oct 18, 2017 TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. PR Newswires
  • Oct 18, 2017 Clinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains PR Newswires
  • Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA PR Newswires
  • Oct 14, 2017 DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact the Firm PR Newswires
  • Oct 11, 2017 INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) PR Newswires
  • Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 PR Newswires
  • Oct 6, 2017 TEVA PHARMACEUTICAL SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited – (TEVA) PR Newswires
  • Oct 5, 2017 Teva Announces tomy s Award Winner at Oncology Satellite Symposium During the 7(th) International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy PR Newswires

Loading more news…

There is no more news available.

Major Holders

Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals

Feedback on our new quotes?EMAIL US

Key Stock Data

Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which provides patient-centric healthcare solutions.

Key Executives

Competitors (TEVA)

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided as is for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright 2017 © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright 2017 FactSet Research Systems Inc. All rights reserved.


Last Updated on: August 27th, 2018 at 2:27 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *